Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Receivables: 2020-2023

Historic Change in Receivables for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$12,417.

  • Immuneering's Change in Receivables rose 98.97% to -$1,046 in Q2 2023 from the same period last year, while for Jun 2023 it was -$178,425, marking a year-over-year increase of 47.88%. This contributed to the annual value of -$12,417 for FY2023, which is 94.69% up from last year.
  • Per Immuneering's latest filing, its Change in Receivables stood at -$12,417 for FY2023, which was up 94.69% from -$233,623 recorded in FY2022.
  • In the past 5 years, Immuneering's Change in Receivables registered a high of $290,170 during FY2020, and its lowest value of -$279,713 during FY2021.
  • Over the past 3 years, Immuneering's median Change in Receivables value was -$233,623 (recorded in 2022), while the average stood at -$175,251.
  • Its Change in Receivables has fluctuated over the past 5 years, first slumped by 196.40% in 2021, then soared by 94.69% in 2023.
  • Over the past 4 years, Immuneering's Change in Receivables (Yearly) stood at $290,170 in 2020, then crashed by 196.40% to -$279,713 in 2021, then increased by 16.48% to -$233,623 in 2022, then skyrocketed by 94.69% to -$12,417 in 2023.